

April 6, 2022

Announcement on Changes of the Board of Directors and Corporate Officers

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara) announced that it decided changes of the Board of Directors and Corporate Officers at a meeting of its Board of Directors held today, as follows:

The appointments for candidates of the Board of Directors will be resolved at the 74th Annual Shareholders Meeting scheduled for late June 2022. The changes and appointments of the Board of Directors and Corporate Officers will be officially decided at a meeting of the Board of Directors to be held on the same day after the Annual Shareholders Meeting.

1. Changes of the position of the Board of Directors (scheduled for late June 2022):

Incumbent of the Board of Directors will be re-appointed.

*: Masao Nomura, Akiko Okuno and Shusaku Nagae, all Outside Directors, will be re-appointed.

2. Changes of Corporate Officers (Scheduled for late June 2022)

Except for the following candidates of Corporate Officer, incumbent Corporate Officers will be re-appointed.

- New candidate of Corporate Officer

Corporate Officer Tatsuya Okamoto, Director, Oncology Clinical Development Divison/
Clinical Science / NV Strategic Planning

- Resigning Corporate Officer

Corporate Officer Keiji Masui, Representative Director, Ono Pharma UD, Co., Ltd.

*: After resigning, he will be appointed as a partner

< Reference >

The followings are the appointments of the Board of Directors, Audit & Supervisory Board Members as well as Corporate Officers (Scheduled for late June 2022).

*: Candidates of the Board of Directors, Audit & Supervisory Board Members and Corporate Officer for subject to approval at the 74th Annual Shareholders Meeting

The Board of Directors:

- Gyo Sagara* President, Representative Director
- Toshihiro Tsujinaka* Senior Executive Officer, Executive Director, Corporate Strategy & Planning
- Toichi Takino* Senior Executive Officer, Executive Director, Discovery & Research
- Isao Ono* Executive Officer, Director, Corporate Research
- Kiyoaki Idemitsu* Executive Officer, Executive Director, Clinical Development
- Masao Nomura* Outside Director
- Akiko Okuno* Outside Director
- Shusaku Nagae* Outside Director

Audit & Supervisory Board Members:

- Katsuyoshi Nishimura Audit & Supervisory Board Member (full-time)
- Hironobu Tanisaka Audit & Supervisory Board Member (full-time)
- Yasuo Hishiyama Outside Audit & Supervisory Board Member
- Akiko Tanabe Outside Audit & Supervisory Board Member

Corporate Officers:

- Yukio Tani Corporate Executive Officer, Head of Corporate Communications/ CSR Promotion
- Shozo Matsuoka Corporate Executive Officer, Executive Director, Corporate Regulatory Compliance, Safety and Quality Assurance
- Satoshi Numata Corporate Executive Officer, Executive Director, Digital & IT Strategy, Global IT Strategy & Planning Dept.
- Hiroshi Ichikawa Corporate Officer, Senior Director , Medical External Affairs
- Katsuji Teranishi Corporate Officer, Division Director, Wholesales Management and Planning/Primary Care Business Division
- Hiromu Habashita Corporate Officer, Deputy Executive Director, Discovery & Research
- Shinji Takai Corporate Officer, Head of Medical Affairs
- Masaki Ito Corporate Officer, Senior Director, Corporate Planning
- Akira Takada Corporate Officer, Executive Director, CMC & Production
- Satoshi Takahagi Corporate Officer, Executive Director, Sales and Marketing, Primary Care Business Division
- Tatsuya Okamaoto Corporate Officer, Director, Oncology Clinical Development Divison/ Clinical Science/ NV Strategic Planning